68 Adjuvant chemotherapy in WHO Grade 2 Astrocytoma: Retrospective Analysis at NNUH to Inform a Multicentre Comparative Study

Clicks: 12
ID: 326799
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #281 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The optimal adjuvant chemotherapy for WHO grade 2 astrocytoma remains uncertain. UK NICE guidance recommends radiotherapy followed by PCV chemotherapy in higher-risk patients; however, temozolomide (TMZ) is sometimes used due to efficacy data in grade 3 astrocytoma as well as its favourable tolerability and ease of administration. No randomised trials directly compare PCV and TMZ in this population, and real-world data on toxicity, treatment adherence, and outcomes remain limited. Retrospective analyses can provide valuable insight into contemporary practice, feasibility, and comparative effectiveness. Method In a retrospective review of patients with WHO grade 2 astrocytoma treated at Norfolk and Norwich University Hospital from 2016 we identified 21 patients who met molecular criteria for grade 2 astrocytoma and received adjuvant chemotherapy. All patients received PCV. Data for patients prior to WHO 2016 criteria is limited by incomplete molecular data. Building on this experience, we propose a UK multicentre retrospective cohort study comparing adjuvant PCV versus TMZ in adults (≥18 years) with histologically confirmed, IDH-mutant, 1p/19q non-codeleted grade 2 astrocytoma treated with surgery and radiotherapy followed by adjuvant chemotherapy. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), treatment-related toxicity, and treatment completion rates. Given the prolonged natural history of this disease, the immediate aim is to generate comparative data on treatment patterns, PFS, and toxicity, providing a foundation for future OS analyses. Conclusions The proposed multicentre retrospective study will provide the largest UK comparative analysis of adjuvant PCV versus TMZ in WHO grade 2 astrocytoma, integrating survival and toxicity outcomes to inform clinical decision-making and future prospective or registry-based research. If you would like to participate in the multicentre study or receive further information, please contact clare.hannon@nnuh.nhs.uk
Reference Key
openalex_W7204479418 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors C. Hannon, Rebecca Brooks, Pinelopi Gkogkou, Andrew Ho
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.052
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.052/70805945/noag172.052.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.